Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0XDRGN |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-Nectin-4 antibody |
|||||
| Antigen Name | Nectin-4 (NECTIN4) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMAWVRQAPGKGLEWVSFISNLAYIGIN
YADTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGARATGWFAYWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIQMTQSPSSLSASVGDRVTITCKASQNVDTHVAWYQQKPGKAPKALIYSASYRYSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPLTFGGGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
LY4101174 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients have specified advanced solid tumors (urothelial, TNBC, NSCLC, etc.) with disease progression after prior therapies (requirements vary by cohort). Key requirements include ECOG 0-1, measurable disease (except Cohort A1), and available tumor tissue. Exclusion criteria include CNS metastases, uncontrolled comorbidities (hypercalcemia, diabetes), corneal disease, recent thromboembolic events, QTcF ≥470ms, or active infections.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06238479 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors
|
||||
| Primary Endpoint |
The Phase 1a primary objective is to establish LY4101174's recommended dose based on dose-limiting toxicities (DLTs) observed within the first two 28-day cycles. Phase 1b evaluates antitumor activity through overall response rate (ORR) as per RECIST 1.1 criteria over approximately 4 years.
|
||||
| Other Endpoint |
Pharmacokinetic analysis assesses minimum plasma concentration (Cmin) and area under curve (AUC) during initial treatment cycles (56 days). Antitumor evaluation includes multiple efficacy measures: ORR, duration of response (DOR), time to response (TTR), progression-free survival (PFS), disease control rate (DCR) and overall survival (OS) - all assessed per RECIST 1.1 over ~4 years.
Click to Show/Hide
|
||||
References